Abstract Background The Infectious Diseases Society of America is committed to providing
up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance …

Carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRAB) is one of
the top-priority pathogens for new antibiotic development. Unlike other antibiotic-resistant …

Background An urgent need exists for antibiotics to treat infections caused by carbapenem-
resistant Acinetobacter baumannii–calcoaceticus complex (ABC). Sulbactam–durlobactam …

Acinetobacter baumannii is recognized as a clinically significant pathogen causing a wide
spectrum of nosocomial infections. Colistin was considered a last-resort antibiotic for the …

Gram-negative bacterial resistance to antimicrobials has had an exponential increase at a
global level during the last decades and represent an everyday challenge, especially for the …

Abstract Sulbactam/durlobactam (XACDURO®), is a co-packaged antibacterial product that
has been developed by Entasis Therapeutics Inc. for the treatment of infections caused by …

Sulbactam-durlobactam is a β-lactam/β-lactamase inhibitor combination currently in
development for the treatment of infections caused by Acinetobacter, including multidrug …

Acinetobacter baumannii-calcoaceticus complex (ABC) causes severe infections that are
difficult to treat due to pre-existing antibiotic resistance. Sulbactam-durlobactam (SUL-DUR) …

Sulbactam-durlobactam is a pathogen-targeted β-lactam/β-lactamase inhibitor combination
in late-stage development for the treatment of Acinetobacter infections, including those …

Carbapenem‐resistant Acinetobacter baumannii (CRAB) is a difficult‐to‐treat nosocomial
pathogen responsible for significant morbidity and mortality. Sulbactam‐durlobactam (SUL …